Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAPPHIRE: Supraschoroidal CLS-TA + intravitreal aflibercept in retinal vein occlusion
2016-004648-12Phase 3Terminated
- Sponsor
- Clearside Biomedical
- Start
- Apr 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aflibercept and triamcinolone acetonide in Vein occlusion (RVO) (2 arms), sponsored by Clearside Biomedical. Primary endpoint: Proportion of subjects with ≥15-letter BCVA improvement at Month 2. Started Apr 2017; status: terminated.
02
Drugs
aflibercepttriamcinolone acetonide
03
Conditions
Vein occlusion (RVO)
Beyond the preview
Go deeper on 2016-004648-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004648-12.